AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline

AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.

Head of business development at AstraZeneca, Shaun Grady
AstraZeneca's Shaun Grady

Business development activity lies at the heart of AstraZeneca PLC’s hopes to return to growth in 2017 after the loss this year of patent protection for its mega-blockbuster statin Crestor (rosuvastatin) in the US – a challenge that follows the patent expiry in 2015 of proton-pump inhibitor Nexium (esomeprazole) while the loss of patent protection still awaits antipsychotic Seroquel XR (quetiapine extended release) in 2017. Still, management is confident it can navigate those threats while also increasing the focus on future growth drivers that the company says will produce an eventual turnaround.

Oncology is one area where the company has made significant progress, although it still has a way to go before...

More from Business Strategy

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.